Established in 2010, our company has already raised €16.5M.

Key facts:

Seventure Partners / Health For Life Capital, Europe’s leading microbiome innovation investment fund, is our historic lead investor.

We are backed by renowned and valuable investors.

Two family offices have also backed LNC, as well as public investors, including the Nouvelle Aquitaine region. We also received support from BPI France.

To achieve our ambitious strategy to become a leading biotech company in the development of microbiome-based therapies, we are open to welcome new investors in our portfolio.

Want to talk to our CEO?

Leveraging partnership
for our success

Microbiome & us
Nov 5, 2019
LNC Therapeutics Announces Formation of its Scientific Advisory Board | Appoints international experts with...
> more
Oct 22, 2019
LNC Therapeutics chooses Luina Bio for the development and GMP manufacturing of its first live bio therapeutic product...
> more
Press / Media
Sep 6, 2019
Chaque semaine, Maddyness dresse le bilan des levées de fonds de la semaine qui vient de s’écouler. Cette semaine,...
> more
Sep 5, 2019
Capital increase supported by the Company’s historic shareholders, including Seventure Partners and a new family office...
> more
Jan 11, 2019
Comparison of the Gut Microbiota of Centenarians in Longevity Villages of South Korea with Those of Other Age Groups...
> more
Jan 2, 2019
Gut Microbes and Health: A Focus on the Mechanisms Linking Microbes, Obesity, and Related Disorders   Marialetizia...
> more
now on twitter
LNC Therapeutics

Researchers have found that people with a certain type of bacteria in their gut may be at a greater risk of develop…

LNC Therapeutics © 2019 - all rights reserved terms and conditions